RxDoctor Payments Data

William Oleksak, MD

Internal Medicine · Ford City, PANPI 1023131307

Payments from drug & device makers

$955in general payments, 2019–2025

Across 48 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$271
  • AbbVie$109
  • Inari Medical, Inc.$90
  • Boston Scientific$77
  • Takeda Pharmaceuticals U.S.A., Inc.$74
  • Abbott$65
  • plus $269 from 11 others

What the payments were for

  • Food & beverage$955100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$955 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$110,765
Medicare patients
314
Services billed
1,359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban192$183,131
JardianceEmpagliflozin126$133,982
JanuviaSitagliptin Phosphate96$130,278
OzempicSemaglutide74$98,086
XareltoRivaroxaban54$54,340
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$45,817
TrulicityDulaglutide24$37,969
Stiolto RespimatTiotropium Br/Olodaterol Hcl61$32,892
MyrbetriqMirabegron38$27,553
TradjentaLinagliptin30$24,040
FarxigaDapagliflozin Propanediol16$21,151
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$16,389
Lantus SolostarInsulin Glargine,hum.Rec.Anlog78$16,057
Atorvastatin Calcium951$13,069
Spiriva RespimatTiotropium Bromide20$10,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta, Spiriva Respimat$35$201,502237 claims
PfizerEliquis$18$183,131192 claims
MerckJanuvia$12$130,27896 claims
Novo NordiskOzempic$271$98,08674 claims
GSKTrelegy Ellipta, Breo Ellipta$13$56,24770 claims
Johnson & JohnsonXarelto$41$54,34054 claims
Lilly USA, LLCTrulicity$22$37,96924 claims
Astellas Pharma US IncMyrbetriq$16$27,55338 claims
NovartisEntresto$34$10,47411 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$74$10,35414 claims
AbbVieSynthroid$109$5,760170 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Ford City

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →